Agenus Reports Upbeat Additional Results

Agenus Inc. (Nasdaq: AGEN) reported additional upbeat results from a Phase 2 study of its brain cancer vaccine Prophage Series G-100. Shares of the biotechnology firm rose 28 cents to close at $3.02.